Stryker (NYSE:SYK) agreed to pay $1.5 million in legal fees to settle a pair of derivatives lawsuits filed by shareholders in 2010.

The Kalamazoo, Mich.-based medical device company admitted no wrongdoing in the settlement, but agreed to institute reforms aimed at preventing future regulatory and legal problems.

The lawsuits, filed in the U.S. District Court for Western Michigan, stemmed from a series of problems that afflicted Stryker and its biotech arm. In addition to paying legal fees, Stryker agreed to install a new committee to prevent violations of the False Claims Act and the Foreign Corrupt Practices Act, according to court documents.

Sign up to get our free newsletters delivered straight to your inbox

The agreement is aimed at preventing the kind of problems that led to warning letters and the recall of Stryker’s Trident hip implant.

It’s also designed to thwart a recurrence of the allegedly illegal cross-label promotion that forced Stryker to ditch its OP-1 bone putty and led to the criminal indictments (and eventual dismissals) for Stryker Biotech and 4 former executives.